NCT01077193

Brief Summary

Up to 45 men and women who meet the entry criteria will undergo the gastric plication procedure. The study will assess subject excess weight loss (%EWL) following the study procedure at 1, 3, 6, 12, 18, 24, 30 and 36 months.

Trial Health

60
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2009

Typical duration for not_applicable

Geographic Reach
2 countries

3 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2009

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 25, 2010

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 1, 2010

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2012

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

September 13, 2013

Completed
Last Updated

February 7, 2014

Status Verified

January 1, 2014

Enrollment Period

2.5 years

First QC Date

February 25, 2010

Results QC Date

July 9, 2013

Last Update Submit

January 8, 2014

Conditions

Keywords

BariatricObesity

Outcome Measures

Primary Outcomes (1)

  • Mean Percent Excess Weight Loss at 3 Years With Last Observation Carried Forward

    Percent excess weight change from baseline to 3 years was calculated as (the baseline weight minus the weight at 3 years) divided by the (baseline weight minus the ideal body weight (using the upper limit of the midpoint range in the Metropolitan Tables for Life Insurance, 1983) x 100). Last observation carried forward was used for early terminated subjects. One-sided, alpha=0.025, t-test of the Percent Excess Weight Loss (EWL) at 3-years to demonstrate non-inferiority to the target weight loss value of 41.1%EWL

    3 years

Study Arms (1)

Gastric Plication Surgery

OTHER
Procedure: Gastric Plication

Interventions

A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.

Gastric Plication Surgery

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is willing to give consent and comply with evaluation and treatment schedule (for female patients, this includes agreement to use a reliable (per investigator) form of birth control for the duration of the trial);
  • to 65 years of age (inclusive);
  • Subject meets ASMBS and NIH criteria: (consensus.nih.gov)
  • BMI ³ 40 kg/m2 and £ 50 kg/m2; or, BMI 35-40 kg/m2 with one or more significant co-morbid medical conditions which are generally expected to be improved, reversed, or resolved by weight loss, including:
  • Hyperlipidemia
  • Mild obstructive sleep apnea (per Investigator discretion)
  • Hypertension
  • Osteoarthritis of the hip or knee per investigational site's criteria for which the subject is being treated;
  • ASA Class I - III;
  • Agree to refrain from any type of weight-loss drug (prescription or OTC) or elective procedure that would affect body weight for the duration of the trial;
  • HbA1C \< 11%; and
  • For subjects who have Type 2 diabetes, medication regimen is no more complex (2 oral medications) than oral metformin plus one oral sulfonylurea plus once daily insulin injection.

You may not qualify if:

  • Documented history of drug and/or alcohol abuse within two (2) years of the Screening Visit;
  • Previous malabsorptive or restrictive procedures performed for the treatment of obesity;
  • Scheduled concurrent surgical procedure, with the exception of SOC liver biopsy;
  • Women of childbearing potential who are pregnant or lactating at the time of screening or at the time of surgery;
  • Psychiatric disorders that may affect compliance with the clinical trial, including dementia, active psychosis, severe depression requiring \> 2 medications, or history of suicide attempts;
  • Participation in any other investigational device or drug study (non-survey based trial; long-term enrollment in such studies as requiring periodic laboratory tests, etc., would be allowed) within 12 weeks of enrollment;
  • Any condition which precludes compliance with the study, including:
  • Inflammatory diseases of the gastrointestinal tract, including severe intractable esophagitis, gastric ulceration, duodenal ulceration, or specific inflammation such as Crohn's disease or ulcerative colitis that have been active within the past 10 years;
  • Congenital or acquired anomalies of the GI tract, including atresias or stenosis;
  • Severe cardiopulmonary disease or other serious organic disease that makes the subject a high-risk surgical candidate;
  • Uncontrolled hypertension;
  • Portal hypertension;
  • Chronic or acute upper gastrointestinal bleeding conditions (e.g., gastric or esophageal varices);
  • Cirrhosis;
  • Congenital or acquired intestinal telangiectasia;
  • +11 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

The Ohio State University Medical Center

Columbus, Ohio, 43210, United States

Location

OB Klinika, a.s.

Prague, Czechia

Location

MeSH Terms

Conditions

Obesity, MorbidObesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Michael L. Schwiers
Organization
Ethicon-Endo Surgery, Inc.

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 25, 2010

First Posted

March 1, 2010

Study Start

November 1, 2009

Primary Completion

May 1, 2012

Study Completion

May 1, 2012

Last Updated

February 7, 2014

Results First Posted

September 13, 2013

Record last verified: 2014-01

Locations